Literature DB >> 17055412

Towards the discovery of drug-like RNA ligands?

Nicolas Foloppe1, Natalia Matassova, Fareed Aboul-Ela.   

Abstract

Targeting RNA with small molecule drugs is an area of great potential for therapeutic treatment of infections and possibly genetic and autoimmune diseases. However, a mature set of precedents and established methodology is lacking. The physicochemical properties of RNA raise specific issues and obstacles to development, and contribute to explain the distinct characteristics of natural RNA ligands, including antibiotics. Yet, RNA-targeting strategies are being implemented to reinvigorate antibacterial discovery by using the ribosomal X-ray structures to modify known antibiotics. To exploit further these structures, we suggest the use of existing protein kinase-directed libraries of drug-like compounds to target the A-site of the bacterial ribosome, on the basis of a specific structural hypothesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17055412     DOI: 10.1016/j.drudis.2006.09.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  18 in total

1.  Targeting microRNAs with small molecules: from dream to reality.

Authors:  S Zhang; L Chen; E J Jung; G A Calin
Journal:  Clin Pharmacol Ther       Date:  2010-04-28       Impact factor: 6.875

2.  Synthesis and stereospecificity of 4,5-disubstituted oxazolidinone ligands binding to T-box riboswitch RNA.

Authors:  Crina M Orac; Shu Zhou; John A Means; David Boehm; Stephen C Bergmeier; Jennifer V Hines
Journal:  J Med Chem       Date:  2011-08-31       Impact factor: 7.446

3.  Docking to RNA via root-mean-square-deviation-driven energy minimization with flexible ligands and flexible targets.

Authors:  Christophe Guilbert; Thomas L James
Journal:  J Chem Inf Model       Date:  2008-05-30       Impact factor: 4.956

4.  MicroRNAs as mediators of cardiovascular disease: Targets to be manipulated.

Authors:  Seahyoung Lee; Eunhyun Choi; Sung-Man Kim; Ki-Chul Hwang
Journal:  World J Biol Chem       Date:  2015-05-26

Review 5.  Advances in targeting nucleocapsid-nucleic acid interactions in HIV-1 therapy.

Authors:  Divita Garg; Bruce E Torbett
Journal:  Virus Res       Date:  2014-07-12       Impact factor: 3.303

6.  1,3-Diazepanes of natural product-like complexity from cyanamide-induced rearrangement of epoxy-delta-lactams.

Authors:  Sanjay Dutta; Cody J Higginson; Bao T Ho; Kevin D Rynearson; Sergey M Dibrov; Thomas Hermann
Journal:  Org Lett       Date:  2010-01-15       Impact factor: 6.005

7.  Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1).

Authors:  Peter C Gareiss; Krzysztof Sobczak; Brian R McNaughton; Prakash B Palde; Charles A Thornton; Benjamin L Miller
Journal:  J Am Chem Soc       Date:  2008-12-03       Impact factor: 15.419

Review 8.  Amino acid recognition and gene regulation by riboswitches.

Authors:  Alexander Serganov; Dinshaw J Patel
Journal:  Biochim Biophys Acta       Date:  2009-07-18

9.  Screening for inhibitors of the hepatitis C virus internal ribosome entry site RNA.

Authors:  Shou Zhou; Kevin D Rynearson; Kejia Ding; Nicholas D Brunn; Thomas Hermann
Journal:  Bioorg Med Chem       Date:  2013-04-02       Impact factor: 3.641

10.  Multivalent binding oligomers inhibit HIV Tat-TAR interaction critical for viral replication.

Authors:  Deyun Wang; Jaclyn Iera; Heather Baker; Priscilla Hogan; Roger Ptak; Lu Yang; Tracy Hartman; Robert W Buckheit; Alexandre Desjardins; Ao Yang; Pascale Legault; Venkat Yedavalli; Kuan-Teh Jeang; Daniel H Appella
Journal:  Bioorg Med Chem Lett       Date:  2009-10-23       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.